A Phase 2 Pilot Study to Assess ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Phase 2
Completed
- Conditions
- Diarrhea Predominant Irritable Bowel Syndrome
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-07-11
- Last Posted Date
- 2019-06-06
- Lead Sponsor
- Seldar Pharma, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT01896583
- Locations
- 🇺🇸
San Marcus Research Clinic Inc, Miami, Florida, United States
🇺🇸PMG Research of Winston-Salem, LLC, Winston-Salem, North Carolina, United States
🇺🇸Probe Clinical Research Group, Santa Ana, California, United States
© Copyright 2025. All Rights Reserved by MedPath